Wechselwirkungen · Zebinix
Zebinix 200 mg tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-120837 · Präparat HOS-095225
6 There was an average decrease of 36-39% in systemic exposure in healthy subjects when co-administered with eslicarbazepine acetate 1,200 mg once daily. The mechanism for this reduction is unknown, but could be due to interference of transporter activity for rosuvastatin alone or in combination with induction of its metabolism. Since the relationship between exposure and drug activity is unclear, the monitoring of response to therapy (e.g., cholesterol levels) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) cholesterol (HOS-087961)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage fa6d27cbc82a21288339e4f7f46bb93471086af14bcf8331561e4329f38445f9 · Zeichen 5105–5587 im Abschnitt